TOT BIOPHARM International Company Limited (1875.HK)

2.510 -0.070 (-2.71%) As of 01:00PM HKT. Market open.

TOT BIOPHARM International Company Limited

No. 120 Changyang Street
Suzhou Industrial Park
Suzhou 215024
China
86 512 6296 5186
https://www.totbiopharm.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 552

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jun Liu	CEO, Chief Scientific Officer & Executive Director	4.25M	N/A	1968
Ms. Ben Xiao	Executive Finance Director	N/A	N/A	1982
Mr. Wing Yat Lui	Joint Company Secretary	N/A	N/A	1990
Mr. Yifan Chen	Joint Company Secretary	N/A	N/A	1980

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

TOT BIOPHARM International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in China. The company develops and markets Pusintin, a bevacizumab injection for the treatment of non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; cervical cancer; and hepatocellular carcinoma. It also offers Tazian, a temozolomide capsule for the treatment of glioblastoma multiforme or anaplastic astrocytoma; and Megaxia, a megestrol acetate oral suspension for the treatment of anorexia associated with acquired immunode¬ciency syndrome, as well as signi¬cant weight loss of AIDS and cancer patients caused by cachexia. In addition, the company is developing TAB014 that has completed Phase III clinical trial for the treatment of wet age-related macular degeneration (wAMD). Further, it develops products under preclinical trials, including TAE020 for acute myeloid leukemia; and TAC020 for the treatment various solid tumors. Additionally, the company engages in contract development and manufacturing organization (CDMO)/contract manufacture organization (CMO) business; and license-out of self-developed biological drugs. TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, China.

Corporate governance

TOT BIOPHARM International Company Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.